Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Clark

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Current Hematologic Malignancy Reports|April 29, 2010
Immunotherapeutic strategies in chronic myeloid leukemiaRichard E Clark
Leukemia Research|May 19, 2009
Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemiaRichard E Clark
British Journal of Haematology|November 15, 2020
The chronic myeloid leukaemia story in the United Kingdom since 1960Richard E Clark
Current Hematologic Malignancy Reports|November 9, 2019
Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical PracticeRichard E Clark
British Journal of Haematology|July 27, 2020
Another set of guidelines for chronic myeloid leukaemiaRichard E Clark
Military Medicine|October 3, 2013
Cognitive task analysis-based design and authoring software for simulation trainingAllen Munro, Richard E Clark
Leukemia & Lymphoma|May 11, 2002
Bone turnover following autologous transplantation in multiple myelomaRichard E Clark, William D Fraser
Leukemia & Lymphoma|September 14, 2004
Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinibErnest Heartin, Stephen Walkinshaw, Richard E Clark
Leukemia & Lymphoma|October 21, 2003
CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantationNauman M Butt, Noreen McGinnity, Richard E Clark
Experimental Hematology|June 9, 2012
Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cellsLihui Wang, Athina Giannoudis, Gemma Austin, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Current Hematologic Malignancy Reports|April 29, 2010
Immunotherapeutic strategies in chronic myeloid leukemiaRichard E Clark
Leukemia Research|May 19, 2009
Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemiaRichard E Clark
British Journal of Haematology|November 15, 2020
The chronic myeloid leukaemia story in the United Kingdom since 1960Richard E Clark
Current Hematologic Malignancy Reports|November 9, 2019
Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical PracticeRichard E Clark
British Journal of Haematology|July 27, 2020
Another set of guidelines for chronic myeloid leukaemiaRichard E Clark
Military Medicine|October 3, 2013
Cognitive task analysis-based design and authoring software for simulation trainingAllen Munro, Richard E Clark
Leukemia & Lymphoma|May 11, 2002
Bone turnover following autologous transplantation in multiple myelomaRichard E Clark, William D Fraser
Leukemia & Lymphoma|September 14, 2004
Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinibErnest Heartin, Stephen Walkinshaw, Richard E Clark
Leukemia & Lymphoma|October 21, 2003
CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantationNauman M Butt, Noreen McGinnity, Richard E Clark
Experimental Hematology|June 9, 2012
Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cellsLihui Wang, Athina Giannoudis, Gemma Austin, et al.
Pageof 12